Department of Obstetrics, Gynecology and Reproduction, Dexeus University Institute, Barcelona, Spain.
Breast Cancer. 2013 Jul;20(3):213-7. doi: 10.1007/s12282-011-0330-1. Epub 2012 Jan 21.
Our aim was to evaluate and compare lymph node involvement, as well as disease-free survival (DFS) and overall survival (OS), between infiltrating ductal carcinoma with (group 1) and without (group 2) intraductal carcinoma component in order to determine the prognostic value of the intraductal component.
Data from 389 cases of infiltrating ductal carcinoma of the breast were included in the study by means of reviewing medical charts and pathology slides.
There was no statistically significant difference between both groups regarding node status. The 5-year DFS rate was 90.7% in group 1 and 81.8% in group 2 (p = 0.014), with a median follow-up of 73.2 months (95% CI 68.3-77.4). There was no statistically significant difference in 5-year OS between groups (98% group 1 vs. 93% group 2) with a median global survival of 134 months (95% CI 131-137).
The presence of intraductal component in the infiltrating carcinoma seems to increase DFS and may be an independent and favorable prognostic factor for breast cancer.
本研究旨在评估和比较浸润性导管癌伴（组 1）和不伴（组 2）导管内癌成分的淋巴结受累情况以及无病生存（DFS）和总生存（OS），以确定导管内成分的预后价值。
通过查阅病历和病理切片，对 389 例乳腺浸润性导管癌病例的数据进行了研究。
两组之间在淋巴结状态方面无统计学差异。组 1 的 5 年 DFS 率为 90.7%，组 2 为 81.8%（p=0.014），中位随访时间为 73.2 个月（95%CI 68.3-77.4）。两组间 5 年 OS 无统计学差异（组 1 为 98%，组 2 为 93%），总生存中位数为 134 个月（95%CI 131-137）。
浸润性癌中存在导管内成分似乎会增加 DFS，并且可能是乳腺癌的一个独立的有利预后因素。
